Vonafexor (EYP001) is a novel selective FXR agonist with anti-HBV effects.

GW4064 (GW-4064) is a novel, potent and selective agonist of farnesoid X receptor (FXR) (EC50 of 65 nM in CV1 cell line) with potential usefulness in the treatment of cholestatic liver disease.

Gly-β-MCA is a bile acid acting as an oral and potent farnesoid X receptor (FXR) inhibitor with the potential to be used for the treatment of metabolic disorders.

Cilofexor, formerly known as GS-9674, is a farnesoid X receptor (FXR) agonist.

Glyco-Obeticholic acid is an active metabolite of Obeticholic acid formed by a phase II metabolic reaction by conjugating with amino acid glycine.

Tauro-Obeticholic acid is an active metabolite of Obeticholic acid (Ocaliva; 6-ECDCA; INT747; 6-Ethylchenodeoxycholic acid) formed by conjugating with taurine, or 2-aminoethanesulfonic acid.

Obeticholic Acid (INT747; 6-ECDCA; 6-Ethylchenodeoxycholic acid; trade name Ocaliva), a novel derivative of cholic acid, is a potent, orally bioactive and selective agonist of farnesoid X receptor (FXR) with EC50 of 99 nM, and has anticholeretic and anti-inflammatory activities.